Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 43.17 USD -7.16% Market Closed
Market Cap: 2.5B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

Relative Value

The Relative Value of one PTGX stock under the Base Case scenario is 18.71 USD. Compared to the current market price of 43.17 USD, Protagonist Therapeutics Inc is Overvalued by 57%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PTGX Relative Value
Base Case
18.71 USD
Overvaluation 57%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
71
vs Industry
56
Median 3Y
10.6
Median 5Y
27.5
Industry
8.1
Forward
8.6
vs History
1
vs Industry
9
Median 3Y
-6.1
Median 5Y
-7.6
Industry
23
Forward
21.6
vs History
1
vs Industry
Median 3Y
-8.6
Median 5Y
-9.8
Industry
23.4
vs History
1
vs Industry
Median 3Y
-8.5
Median 5Y
-9.6
Industry
27.3
vs History
19
vs Industry
24
Median 3Y
3.8
Median 5Y
3.8
Industry
2.6
vs History
60
vs Industry
51
Median 3Y
6.1
Median 5Y
20.1
Industry
8.1
Forward
7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.6
vs History
1
vs Industry
9
Median 3Y
-3.6
Median 5Y
-4.9
Industry
4.3
Forward
10.8
vs History
1
vs Industry
8
Median 3Y
-3.6
Median 5Y
-4.9
Industry
3.8
Forward
18.3
vs History
1
vs Industry
Median 3Y
-5.4
Median 5Y
-6.6
Industry
6
vs History
1
vs Industry
Median 3Y
-5.4
Median 5Y
-6.6
Industry
3.8
vs History
65
vs Industry
29
Median 3Y
35.5
Median 5Y
32.3
Industry
4.8

Multiples Across Competitors

PTGX Competitors Multiples
Protagonist Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
2.6B USD 7.9 15 14 14.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 380 957.8 -177 666.1 -215 743.3 -213 281.4
US
Abbvie Inc
NYSE:ABBV
302.3B USD 5.4 59.5 14.9 22.9
US
Amgen Inc
NASDAQ:AMGN
160.6B USD 4.9 38 17.7 33.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.3B USD 11.9 -263.2 26.7 28
US
Gilead Sciences Inc
NASDAQ:GILD
118.3B USD 4.2 939 10.4 10.4
US
Epizyme Inc
F:EPE
94.1B EUR 1 884.6 -480.9 -523.7 -509.7
AU
CSL Ltd
ASX:CSL
138.5B AUD 6.1 34.3 21.1 26.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
90.4B USD 6.5 19.4 17.9 19.9
US
Seagen Inc
F:SGT
39.3B EUR 18.2 -55.7 -59.8 -54
NL
argenx SE
XBRU:ARGX
33.4B EUR 18.2 -127.9 -102.8 -74.9
P/E Multiple
Earnings Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 184.2
15
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -177 666.1 N/A
US
Abbvie Inc
NYSE:ABBV
59.5
412%
US
Amgen Inc
NASDAQ:AMGN
38
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.2
42%
US
Gilead Sciences Inc
NASDAQ:GILD
939
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -480.9 N/A
AU
CSL Ltd
ASX:CSL
34.3
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -127.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBITDA: 17.5
14
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -215 743.3 N/A
US
Abbvie Inc
NYSE:ABBV
14.9
28%
US
Amgen Inc
NASDAQ:AMGN
17.7
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.7
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -523.7 N/A
AU
CSL Ltd
ASX:CSL
21.1
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -102.8 N/A
EV/EBIT Multiple
EBIT Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average EV/EBIT: 22.1
14.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -213 281.4 N/A
US
Abbvie Inc
NYSE:ABBV
22.9
88%
US
Amgen Inc
NASDAQ:AMGN
33.4
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.4
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -509.7 N/A
AU
CSL Ltd
ASX:CSL
26.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -74.9 N/A

See Also

Discover More
Back to Top